Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 24 | 0 Decreased by -100% | -0.14 Increased by +100% |
| Mar 6, 24 | -0.24 Decreased by -33.33% | -0.1 Decreased by -140% |
| Nov 8, 23 | -0.2 Increased by +16.67% | -0.12 Decreased by -66.67% |
| Aug 9, 23 | -0.23 Increased by +17.86% | -0.13 Decreased by -76.92% |
| May 12, 23 | 0.01 Increased by +103.33% | -0.15 Increased by +106.67% |
| Mar 6, 23 | -0.18 Increased by +25% | -0.25 Increased by +28% |
| Nov 8, 22 | -0.24 Increased by +20% | -0.24 |
| Aug 4, 22 | -0.28 Decreased by -16.67% | -0.25 Decreased by -12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 7.32 M Increased by +4.45% | -45.6 M Decreased by -10.09% | Decreased by -623.05% Decreased by -5.4% |
| Jun 30, 23 | 5.13 M Decreased by -7.37% | -21.39 M Increased by +51.96% | Decreased by -416.94% Increased by +48.14% |
| Mar 31, 23 | 47.6 M Increased by +1.23 K% | 1.04 M Increased by +102.06% | Increased by +2.18% Increased by +100.15% |
| Dec 31, 22 | 11.03 M Increased by +678.26% | -29.25 M Increased by +24.73% | Decreased by -265.23% Increased by +90.33% |
| Sep 30, 22 | 7.01 M Increased by +482.46% | -41.42 M Increased by +2.31% | Decreased by -591.14% Increased by +83.23% |
| Jun 30, 22 | 5.54 M Increased by +78.93% | -44.52 M Decreased by -13.96% | Decreased by -803.9% Increased by +36.31% |
| Mar 31, 22 | 3.58 M Increased by +723.73% | -50.27 M Decreased by -33.11% | Decreased by -1.41 K% Increased by +83.84% |
| Dec 31, 21 | 1.42 M Decreased by -5.66% | -38.86 M Decreased by -6.13% | Decreased by -2.74 K% Decreased by -12.5% |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.